immuno oncology frontiers world miami


Wolfgang Knirsch

Dr Wolfgang Knirsch

CEO, Vita 34 AG
Dr. Wolfgang Knirsch is a Member of the Management Board of Vita 34 since June 2016.
Following successful completion of his doctorate in Inorganic Chemistry at RWTH Aachen, Dr. Knirsch moved from institutional research to the pharmaceutical industry in 1992.
Dr. Knirsch began this career step traditionally in Sales and Marketing at Hoechst AG. Later he was responsible for the product management of internationally relevant ethical preparations of the successor company Aventis Pharma GmbH. After moving to Merck KGaA he was responsible, inter alia, for new business as well as later for the national marketing of the most important drug sector of the company.
In 2005 Dr. Knirsch took on responsibility for strategic and operative marketing at Biotest AG, a specialist in clinical immunology, hematology, intensive and emergency medicine. Following the successful restructuring and reorientation of this area, he moved within that company to their international business in 2011. In his capacity as Vice President International Business, he developed a strategically relevant area of responsibility of several hundred million dollars successfully with global sales partners.
  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy